Subcutaneous Vedolizumab Treatment in a Real-World Inflammatory Bowel Disease Cohort Switched From Intravenous Vedolizumab: Eighteen-Month Prospective Follow-up Study.

Details

Language :

English

Volume :

6

Issue :

1

Database :

Complementary Index

Journal :

Crohn's & Colitis 360

Publication Type :

Academic Journal

Accession number :

176301488

Full Text :

https://doi.org/10.1093/crocol/otae013